Primary Biliary Cholangitis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of primary biliary cholangitis (PBC) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of PBC for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report. In addition to forecasting incident and prevalent patient populations in these markets, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s PBC forecast will answer the following questions:
- Of all people diagnosed with PBC, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PBC over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts nine PBC patient populations, as follows:
- Diagnosed incidence cases of PBC.
- Diagnosed prevalent cases of PBC.
- Diagnosed prevalent cases of PBC based on biopsy.
- PBC by stage of fibrosis.
- Diagnosed prevalent cases of PBC with fatigue.
- Diagnosed prevalent cases of PBC with pruritus.
- Diagnosed prevalent cases of PBC with jaundice.
- Drug-treated prevalent cases of PBC.
- Diagnosed prevalent cases of PBC based on the response to ursodeoxycholic acid (UDCA).
Note: Coverage may vary by country.
Table of contents
- Primary Biliary Cholangitis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of primary biliary cholangitis)
- Diagnosed incident cases
- Diagnosed prevalent cases
- Diagnosed prevalent cases of PBC based on biopsy
- PBC by stage of fibrosis
- Diagnosed prevalent cases of PBC with fatigue
- Diagnosed prevalent cases of PBC with pruritus
- Diagnosed prevalent cases of PBC with jaundice
- Drug-treated prevalent cases of primary biliary cholangitis
- Diagnosed prevalent cases of PBC based on the response to UDCA
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation table
Chaitra Srinivas, M.P.H., Pharm.D., is an associate epidemiologist at DRG, part of Clarivate. Dr. Srinivas obtained a master’s degree in medical sciences with a major in public health epidemiology from the Karolinska Institute in Sweden. She obtained her doctor of pharmacy from Rajiv Gandhi University of Health Sciences in Bangalore, India. Before completing her postgraduate degree, she worked in pharmacovigilance and drug safety and as a clinical pharmacist.